Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
about
Age at First Cardiac Symptoms in Fabry Disease: Association with a Chinese Hotspot Fabry Mutation (IVS4+919G>A), Classical Fabry Mutations, and Sex in a Taiwanese Population from the Fabry Outcome Survey (FOS).Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.Innate and Adaptive Immune Response in Fabry DiseaseUric Acid as a Marker of Mortality and Morbidity in Fabry Disease.Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells.Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease.Globotriaosylsphingosine induces oxidative DNA damage in cultured kidney cells.From Lysosomal Storage Diseases to NKT Cell Activation and BackTetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.Increased urinary CD80 excretion and podocyturia in Fabry disease.Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease.Fabry disease in children: a federal screening programme in Russia.Initially Nondiagnosed Fabry's Disease when Electron Microscopy Is Lacking: The Continuing Story of Focal and Segmental Glomerulosclerosis.Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.Evidence for inflammation in Fabry's disease? Headache and muscle involvement responding to corticosteroid and methotrexate treatment.Characterization of Human Dermal Fibroblasts in Fabry Disease.Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease
P2860
Q33165407-8A4151B7-5ABD-4FE8-B2DE-9C7CE24B81F1Q34577897-A02AA641-9059-465B-A6E3-08295097C348Q35800976-82F132F9-1B0D-4CA3-90EA-AFA33456D941Q36189989-D7619A4A-6841-4FCC-BF69-5A2A615827B8Q36219290-8A74DF4E-FA83-4E1A-9589-92B76AC3C998Q38421318-2F304CD1-42F3-4DFB-83E3-4D9CE50A5B44Q38827299-D462AAFA-DDCE-4D32-AD4B-A4EBAEA7E359Q39154759-50C87020-D9E9-4F41-BBE2-8B2E3FBC86DBQ40351353-7A808BA5-C73A-4B59-96D1-FA6B100ABFFFQ41452180-E932AAC4-4B31-4989-8E68-355B7DBD8A0EQ41689988-8ADD33A9-10B9-471C-991A-65478E157925Q42066201-2FC211EC-BB4A-49D7-91C3-EA033E4C60E8Q42933875-87E0266D-96D5-4B45-8CD2-CFAB62D38C20Q47094778-1709A002-8051-49FF-AA65-3135B7C25626Q48302271-2E61E2A4-B9E4-4747-8C90-1919DAE82043Q52937759-A0CD85EC-E640-4344-A2C1-B7ACD5847FFCQ58691569-49F2DCC8-2E78-43F0-B8E3-A97D49B943B8Q58774531-46DDE8CB-E9D1-458F-8609-028A2DB67116
P2860
Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Globotriaosylceramide is corre ...... th enzyme replacement therapy.
@en
Globotriaosylceramide is corre ...... th enzyme replacement therapy.
@nl
type
label
Globotriaosylceramide is corre ...... th enzyme replacement therapy.
@en
Globotriaosylceramide is corre ...... th enzyme replacement therapy.
@nl
prefLabel
Globotriaosylceramide is corre ...... th enzyme replacement therapy.
@en
Globotriaosylceramide is corre ...... th enzyme replacement therapy.
@nl
P2093
P1476
Globotriaosylceramide is corre ...... ith enzyme replacement therapy
@en
P2093
Camila S Vanzin
Carmen R Vargas
Cristina B O Netto
Daiane B Rodrigues
Giovana B Biancini
Graziela S Ribas
Laura B Jardim
Marion Deon
Roberto Giugliani
Vanusa Manfredini
P304
P356
10.1016/J.BBADIS.2011.11.001
P577
2011-11-06T00:00:00Z